Research programme: antisense therapies - AstraZeneca/Ionis Pharmaceuticals

Drug Profile

Research programme: antisense therapies - AstraZeneca/Ionis Pharmaceuticals

Alternative Names: AZD-4785; AZD8233; IONIS-AZ4-2.5-LRx; IONIS-KRAS-2.5Rx; ISIS 581088

Latest Information Update: 22 May 2017

Price : $50

At a glance

  • Originator Isis Pharmaceuticals
  • Developer AstraZeneca; Ionis Pharmaceuticals
  • Class Antineoplastics; Antisense oligonucleotides; Cardiovascular therapies
  • Mechanism of Action Androgen receptor antagonists; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Cardiovascular disorders
  • Research Kidney disorders; Metabolic disorders

Most Recent Events

  • 13 Apr 2017 AstraZeneca plans a phase I trial of AZD 4785 in Solid tumours, including Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) (NCT03101839)
  • 01 Apr 2017 Pharmacodynamics data from a preclinical trial in Prostate cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 19 Dec 2016 Preclinical trials in Cardiovascular disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top